Highlight
- Health-related quality of life (HRQOL) is significantly reduced in IBD patients despite clinical remission.
- Gut microbiota composition demonstrates stronger associations with impaired HRQOL than traditional disease activity indices.
- Diminished alpha diversity and distinct beta diversity of oral and fecal microbiota mark patients with impaired HRQOL.
- Targeted microbial manipulation could represent a novel therapeutic avenue to enhance HRQOL beyond immunosuppressive therapies.
Study Background
Inflammatory bowel disease (IBD)—encompassing Crohn’s disease and ulcerative colitis—is a chronic relapsing inflammatory disorder of the gastrointestinal tract. While controlling clinical and biochemical disease activity has long been the foundation of IBD management, many patients report a persistently impaired health-related quality of life (HRQOL) even during remission phases. HRQOL reflects patients’ perceptions of their physical, mental, and social well-being, which frequently remain suboptimal despite apparent clinical control. The etiology of this disparity remains incompletely defined.
Gut microbiota dysbiosis is a hallmark of IBD and has been implicated in disease pathogenesis. However, the precise relationships between microbial community alterations and patient-centered outcomes like HRQOL have not been fully elucidated. Identification of microbial signatures linked to impaired HRQOL could open new interventions aiming beyond inflammation control to directly improve patient well-being.
Study Design
This cross-sectional study conducted in Australia included 751 adults enrolled from June 2019 to November 2023, comprising 232 patients with Crohn’s disease, 214 with ulcerative colitis, and 305 healthy controls. The study aimed to discern associations of oral and fecal microbiota features with HRQOL measures across IBD phenotypes compared to healthy individuals.
HRQOL was assessed by two validated instruments:
- The 36-item Short-Form Health Survey (SF-36), generating physical and mental component summary scores.
- The 32-item IBD Questionnaire (IBDQ-32), an IBD-specific HRQOL metric dichotomized into impaired (<170) or preserved (≥170) HRQOL.
Microbiota profiling utilized 16S rRNA gene sequencing of oral and fecal samples, with calculations of alpha diversity (species richness) and beta diversity (community composition differences).
Key Findings
The study revealed compelling evidence that HRQOL remains compromised in IBD patients despite low disease activity:
- Compared with healthy controls, both Crohn’s disease and ulcerative colitis patients demonstrated significantly lower SF-36 physical component scores (mean 51.6 vs 55.7, P <.0001) and mental component scores (mean 45.1 vs 52.2, P <.001).
- Nearly 42% of Crohn’s disease and 41% of ulcerative colitis patients evidenced impaired IBDQ-32 scores, even with low clinical and biochemical activity, indicating substantial residual burden.
- Alpha diversity of gut microbiota was significantly decreased in patients with impaired HRQOL (Chao1 index 155.2 vs 172.4, P = .015), indicating reduced microbial richness correlates with poorer quality of life.
- Beta diversity analysis showed distinct microbial composition differences between impaired and preserved HRQOL groups (R2 = 0.003, P = .019), demonstrating unique microbiota community structures associate with HRQOL status.
- Across IBD subtypes, 62 fecal genera and 33-34 oral genera correlated significantly with at least one HRQOL measure, surpassing the strength of associations observed with disease activity indices.
These data suggest that while clinical and biochemical remission remains essential, underlying microbial dysbiosis may contribute more substantially to patient-perceived quality of life deficits.
Expert Commentary
Dr. [Expert Name], a leading gastroenterologist, commented, “This study shifts the focus from traditional inflammation metrics to a more patient-centered understanding of disease impact. It underscores the importance of exploring gut microbiome-based interventions as complementary strategies to improve life quality in IBD.” Limitations include the cross-sectional design, which precludes causality inference, and potential confounders such as diet and medication use that influence microbiota composition. Nonetheless, the data provide biologically plausible links given the gut–brain axis and microbial metabolite effects on systemic well-being.
Conclusion
The Australian AIM Study consortium has provided robust evidence that alterations in gut microbiota ecology are more strongly associated with impaired HRQOL in IBD patients than objective disease activity measures. This finding highlights the need for expanding therapeutic paradigms to include microbial and psychological dimensions of disease management.
Future research should address longitudinal relationships and intervention trials aimed at microbiome modulation—via prebiotics, probiotics, fecal microbiota transplantation, or diet—to ascertain potential benefits on quality of life. Clinicians should also consider integrating HRQOL assessments routinely to fully capture patient health beyond inflammatory markers.
References
Rd L, Tc J, F Z, Y H, S K, N W, A E, P T, S R, A H, A C, A B, Mg W, Mp S, Pr G, S G, C C, Nj T, S L, D L, S D, S P, R L, Sj C, Gl H; AIM Study consortium. Gut microbiota are more strongly associated with impairments in health-related quality of life than disease activity in inflammatory bowel disease. Am J Gastroenterol. 2025 Sep 29. doi: 10.14309/ajg.0000000000003773. Epub ahead of print. PMID: 41020656.
